Outcomes of Adrenalectomy and the Aldosteronoma Resolution Score in the Black and Hispanic Population.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
accepted:
10
01
2021
pubmed:
9
2
2021
medline:
9
7
2021
entrez:
8
2
2021
Statut:
ppublish
Résumé
Outcomes after adrenalectomy in patients with primary aldosteronism (PA) are variable. The aldosteronoma resolution score (ARS) uses preoperative variables to calculate a score that identifies those patients that are more likely to have resolution of hypertension after adrenalectomy. We aim to determine the efficacy of adrenalectomy and whether the ARS accurately predicts clinical success in a Black and Hispanic population. We reviewed patients who underwent adrenalectomy for PA from 2004 to 2018 at two academic centers treating primarily Hispanic and Black patients. Postoperative outcomes were evaluated based on the primary aldosteronism surgical outcome consensus criterion. Retrospectively, the accuracy of ARS was determined by a receiver operating characteristic curve and the area under the curve (AUC). Forty-three Hispanic and 10 Black patients underwent adrenalectomy for PA. Twenty-two patients (41.5%) had complete clinical success. Variables associated with complete clinical success in the univariate analysis were female gender (p = 0.026), younger age (p = 0.001), lower preoperative aldosterone (p = 0.035), lower preoperative systolic blood pressure (p = 0.001), fewer number of preoperative antihypertensive medications (p = 0.007) and a higher ARS (p = 0.003). On multivariate analysis, only fewer number of preoperative antihypertensive medications was independently associated with complete clinical success (p = 0.026). The AUC of the ARS was 0.746. The rate of clinical success from adrenalectomy is good for Hispanic and Black patients with PA. Our analysis shows that the ARS is an accurate test of clinical success in Hispanic and Black patients. The ARS may be utilized preoperatively to frame expectations after adrenalectomy in these populations.
Sections du résumé
BACKGROUND
Outcomes after adrenalectomy in patients with primary aldosteronism (PA) are variable. The aldosteronoma resolution score (ARS) uses preoperative variables to calculate a score that identifies those patients that are more likely to have resolution of hypertension after adrenalectomy. We aim to determine the efficacy of adrenalectomy and whether the ARS accurately predicts clinical success in a Black and Hispanic population.
METHODS
We reviewed patients who underwent adrenalectomy for PA from 2004 to 2018 at two academic centers treating primarily Hispanic and Black patients. Postoperative outcomes were evaluated based on the primary aldosteronism surgical outcome consensus criterion. Retrospectively, the accuracy of ARS was determined by a receiver operating characteristic curve and the area under the curve (AUC).
RESULTS
Forty-three Hispanic and 10 Black patients underwent adrenalectomy for PA. Twenty-two patients (41.5%) had complete clinical success. Variables associated with complete clinical success in the univariate analysis were female gender (p = 0.026), younger age (p = 0.001), lower preoperative aldosterone (p = 0.035), lower preoperative systolic blood pressure (p = 0.001), fewer number of preoperative antihypertensive medications (p = 0.007) and a higher ARS (p = 0.003). On multivariate analysis, only fewer number of preoperative antihypertensive medications was independently associated with complete clinical success (p = 0.026). The AUC of the ARS was 0.746.
CONCLUSION
The rate of clinical success from adrenalectomy is good for Hispanic and Black patients with PA. Our analysis shows that the ARS is an accurate test of clinical success in Hispanic and Black patients. The ARS may be utilized preoperatively to frame expectations after adrenalectomy in these populations.
Identifiants
pubmed: 33554297
doi: 10.1007/s00268-021-05967-y
pii: 10.1007/s00268-021-05967-y
pmc: PMC8026410
doi:
Substances chimiques
Aldosterone
4964P6T9RB
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1475-1482Références
Funder JW et al (2016) The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101(5):1889–1916
doi: 10.1210/jc.2015-4061
Yang Y, Reincke M, Williams TA (2019) Prevalence, diagnosis and outcomes of treatment for primary aldosteronism. Best Pract Res Clin Endocrinol Metab. https://doi.org/10.1016/j.beem.2019.101365
doi: 10.1016/j.beem.2019.101365
pubmed: 31837980
Vaidya A, Mulatero P, Baudrand R, Adler GK (2018) The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr Rev 39(6):1057–1088. https://doi.org/10.1210/er.2018-00139
doi: 10.1210/er.2018-00139
pubmed: 30124805
pmcid: 6260247
Zarnegar R et al (2008) The Aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg 247(3):511–518. https://doi.org/10.1097/SLA.0b013e318165c075
doi: 10.1097/SLA.0b013e318165c075
pubmed: 18376197
Utsumi T et al (2012) High predictive accuracy of Aldosteronoma resolution score in Japanese patients with aldosterone-producing adenoma. Surgery 151(3):437–443. https://doi.org/10.1016/j.surg.2011.08.001
doi: 10.1016/j.surg.2011.08.001
pubmed: 22000827
Aronova A, Gordon BL, Finnerty BM, Zarnegar R, Fahey TJ (2014) Aldosteronoma resolution score predicts long-term resolution of hypertension. Surgery 156(6):1387–1393. https://doi.org/10.1016/j.surg.2014.08.019
doi: 10.1016/j.surg.2014.08.019
pubmed: 25456916
Pasquier L et al (2017) Assessment of the aldosteronona resolution score as a predictive resolution score of hypertension after adrenalectomy for aldosteronoma in French patients. Langenbecks Arch Surg 402(2):309–314. https://doi.org/10.1007/s00423-017-1557-x
doi: 10.1007/s00423-017-1557-x
pubmed: 28111697
Loh WJ, Lim DST, Loh LM, Kek PC (2018) Factors associated with resolution of hypertension after adrenalectomy in patients with primary aldosteronism. Endocrinol Metab 33(3):355. https://doi.org/10.3803/EnM.2018.33.3.355
doi: 10.3803/EnM.2018.33.3.355
International Connsortium Study Group et al (2019) Validation of the Aldosteronoma Resolution Score Within Current Clinical Practice. World J Surg 43(10):2459–2468. https://doi.org/10.1007/s00268-019-05074-z
doi: 10.1007/s00268-019-05074-z
Kumar J (2013) Epidemiology of hypertension. Clin Queries Nephrol 2(2):56–61. https://doi.org/10.1016/j.cqn.2013.04.005
doi: 10.1016/j.cqn.2013.04.005
Guzman NJ (2012) Epidemiology and management of hypertension in the hispanic population: a review of the available literature. Am J Cardiovasc Drugs 12(3):165–178. https://doi.org/10.2165/11631520-000000000-00000
doi: 10.2165/11631520-000000000-00000
pubmed: 22583147
pmcid: 3624012
Käyser SC et al (2016) Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab 101(7):2826–2835. https://doi.org/10.1210/jc.2016-1472
doi: 10.1210/jc.2016-1472
pubmed: 27172433
Gershuni VM et al (2020) Clinical presentation and surgical outcomes in primary aldosteronism differ by race. J Surg Oncol 121(3):456–464. https://doi.org/10.1002/jso.25806
doi: 10.1002/jso.25806
pubmed: 31858609
Williams TA et al (2017) Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 5(9):689–699. https://doi.org/10.1016/S2213-8587(17)30135-3
doi: 10.1016/S2213-8587(17)30135-3
pubmed: 28576687
pmcid: 5572673
Mandrekar JN (2010) Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol 5(9):1315–1316. https://doi.org/10.1097/JTO.0b013e3181ec173d
doi: 10.1097/JTO.0b013e3181ec173d
pubmed: 20736804
Milliez P, Girerd X, Plouin P-F, Blacher J, Safar ME, Mourad J-J (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45(8):1243–1248. https://doi.org/10.1016/j.jacc.2005.01.015
doi: 10.1016/j.jacc.2005.01.015
pubmed: 15837256
Funder JW (2018) Primary aldosteronism and cardiovascular risk, before and after treatment. Lancet Diabetes Endocrinol 6(1):5–7
doi: 10.1016/S2213-8587(17)30368-6
Catena C et al (2007) Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 50(5):911–918. https://doi.org/10.1161/HYPERTENSIONAHA.107.095448
doi: 10.1161/HYPERTENSIONAHA.107.095448
pubmed: 17893375
Zeiger M et al (2009) American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the management of adrenal incidentalomas. Endocr Pract 15(Supplement 1):1–20. https://doi.org/10.4158/EP.15.S1.1
doi: 10.4158/EP.15.S1.1
pubmed: 19632967
Burrello J et al (2019) The primary aldosteronism surgical outcome score for the prediction of clinical outcomes after adrenalectomy for unilateral primary aldosteronism. Ann Surg. https://doi.org/10.1097/SLA.0000000000003200
doi: 10.1097/SLA.0000000000003200